RESUMEN
BACKGROUND: Limited data are available on the effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis (AD). OBJECTIVE: To investigate COVID-19 outcomes in patients with AD treated with or without systemic immunomodulatory treatments, using a global registry platform. METHODS: Clinicians were encouraged to report cases of COVID-19 in their patients with AD in the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Atopic Dermatitis (SECURE-AD) registry. Data entered from 1 April 2020 to 31 October 2021 were analysed using multivariable logistic regression. The primary outcome was hospitalization from COVID-19, according to AD treatment groups. RESULTS: 442 AD patients (mean age 35.9 years, 51.8% male) from 27 countries with strongly suspected or confirmed COVID-19 were included in analyses. 428 (96.8%) patients were treated with a single systemic therapy (n = 297 [67.2%]) or topical therapy only (n = 131 [29.6%]). Most patients treated with systemic therapies received dupilumab (n = 216). Fourteen patients (3.2%) received a combination of systemic therapies. Twenty-six patients (5.9%) were hospitalized. No deaths were reported. Patients treated with topical treatments had significantly higher odds of hospitalization, compared with those treated with dupilumab monotherapy (odds ratio (OR) 4.65 [95%CI 1.71-14.78]), including after adjustment for confounding variables (adjusted OR (aOR) 4.99 [95%CI 1.4-20.84]). Combination systemic therapy which did not include systemic corticosteroids was associated with increased odds of hospitalization, compared with single agent non-steroidal immunosuppressive systemic treatment (OR 8.09 [95%CI 0.4-59.96], aOR 37.57 [95%CI 1.05-871.11]). Hospitalization was most likely in patients treated with combination systemic therapy which included systemic corticosteroids (OR 40.43 [95%CI 8.16-207.49], aOR 45.75 [95%CI 4.54-616.22]). CONCLUSIONS: Overall, the risk of COVID-19 complications appears low in patients with AD, even when treated with systemic immunomodulatory agents. Dupilumab monotherapy was associated with lower hospitalization than other therapies. Combination systemic treatment, particularly combinations including systemic corticosteroids, was associated with the highest risk of severe COVID-19.
Asunto(s)
COVID-19 , Dermatitis Atópica , Humanos , Masculino , Adulto , Femenino , Dermatitis Atópica/tratamiento farmacológico , Resultado del Tratamiento , Corticoesteroides/uso terapéutico , Sistema de Registros , Índice de Severidad de la EnfermedadRESUMEN
In this case series, we report for the first time in the literature in a cohort, the positive response to oral or topical antifungals for atopic dermatitis patients treated with Dupilumab that developed Dupilumab facial redness, supporting the Malassezia hypersensitivity theory.
Asunto(s)
Dermatitis Atópica , Eccema , Anticuerpos Monoclonales Humanizados/efectos adversos , Dermatitis Atópica/inducido químicamente , Dermatitis Atópica/tratamiento farmacológico , Eritema/inducido químicamente , HumanosAsunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , COVID-19/inmunología , Dermatitis Atópica/tratamiento farmacológico , Fármacos Dermatológicos/administración & dosificación , SARS-CoV-2/inmunología , Anticuerpos Monoclonales Humanizados/efectos adversos , COVID-19/diagnóstico , COVID-19/virología , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/inmunología , Fármacos Dermatológicos/efectos adversos , Esquema de Medicación , Interacciones Huésped-Patógeno , Humanos , Huésped Inmunocomprometido , Masculino , Medición de Riesgo , Resultado del Tratamiento , Adulto JovenAsunto(s)
Melanoma Amelanótico/secundario , Melanoma Amelanótico/terapia , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/terapia , Quimioterapia Adyuvante , Niño , Humanos , Rodilla , Escisión del Ganglio Linfático , Metástasis Linfática , Masculino , Melanoma Amelanótico/diagnóstico , Neoplasias Cutáneas/diagnósticoRESUMEN
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) are endemic diseases in America, especially in some countries such as Colombia. Among the therapeutic options is amphotericin B (AB). Nevertheless, its lipid-associated formulations have better safety profiles and effectiveness in other diseases, so far with no comparative studies in CL or MCL. We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL. The effectiveness of LAB (88.5%) was greater than those of ABCD (66.6%) and ABD (80.8%). There were also fewer adverse effects in the LAB group (46.2%) than in the ABD (96.1%) and ABCD (80.9%) groups. LAB is an alternative for the treatment of CL and MCL in patients with therapeutic failure to first- and second-line drugs; findings suggest it might be less toxic and more effective than ABD and ABCD.
Asunto(s)
Anfotericina B/efectos adversos , Anfotericina B/uso terapéutico , Ácido Desoxicólico/uso terapéutico , Leishmaniasis Cutánea/tratamiento farmacológico , Leishmaniasis Mucocutánea/tratamiento farmacológico , Antiprotozoarios/efectos adversos , Antiprotozoarios/uso terapéutico , Coloides , Colombia/epidemiología , Ácido Desoxicólico/efectos adversos , Combinación de Medicamentos , Humanos , Leishmaniasis Cutánea/epidemiología , Leishmaniasis Mucocutánea/epidemiología , Estudios RetrospectivosAsunto(s)
Neoplasias Hematológicas , Neoplasias Cutáneas , Colombia , Estudios Transversales , Femenino , Humanos , Derivación y ConsultaAsunto(s)
Humanos , Femenino , Neoplasias Cutáneas , Neoplasias Hematológicas , Derivación y Consulta , Estudios Transversales , ColombiaRESUMEN
El libro resalta que la lepra continúa siendo una enfermedad presente en Colombia y que aún constituye un problema de salud pública importante por los costos sociales, económicos y de sufrimiento humano que conlleva. Sabiendo que la literatura sobre el tema es escasa en nuestro medio, este libro surge como una herramienta de consulta creada para médicos y otros profesionales de salud, con la certeza de que es preciso mejorar la oportunidad del diagnóstico. Siendo fundamental que, durante su proceso formativo, todos los profesionales de la salud adquieran conocimientos sobre dicha enfermedad, que cada día se hace más visible por sus secuelas y diagnóstico tardío.
The book highlights the fact that leprosy continues to be a disease present in Colombia and that it is still a major public health problem due to the social, economic and human suffering costs it entails. Knowing that the literature on the subject is scarce in our country, this book is intended as a reference tool for doctors and other health professionals, in the knowledge that it is necessary to improve the timeliness of diagnosis. It is essential that, during their training process, all health professionals acquire knowledge about this disease, which is becoming more and more visible every day due to its sequelae and late diagnosis.